Kyowa Kirin, Inc., anchored by its North American headquarters in Princeton, on Monday announced a voluntary agreement with the U.S. government aimed at expanding patient access and reducing treatment costs for Americans.
Under the agreement, the specialty pharmaceutical company will participate in the federal GENEROUS model—offering specific medicines at a discount to state Medicaid patients—while committing to launch future products in developed nations under a more balanced global pricing framework. In tandem with the pricing framework, Kyowa Kirin also secured an agreement with the U.S. Department of Commerce to defer Section 232 tariffs.
“This agreement reflects our ongoing efforts to advocate for broad patient access; we believe in the importance of strengthening the resilience and viability of health systems worldwide and stand ready to work constructively on global initiatives that support access to life-changing therapies,” Abdul Mullick, president and CEO of Kyowa Kirin said. “We appreciate our ongoing partnership with the U.S. government and believe this is a pragmatic step toward offering breakthrough medicines to patients.”
While its corporate operational footprint spans international research hubs—including a long-standing antibody and cell-therapy research facility in La Jolla, California, and a major $530 million biomanufacturing facility under construction in Sanford, North Carolina—the company directs its North American operations from its central New Jersey base in Princeton.
Company leadership emphasized that the collaborative step with federal regulators paves the way for continued biopharmaceutical innovation within the United States while simultaneously advancing research pipelines targeting orphan diseases worldwide. Detailed financial and structural terms of the voluntary agreement remain confidential.
